Procter & Gamble Health DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY27Jun 2026FY26Jun 2025FY25Jun 2024FY24Jun 2023FY23 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY23 and earlierEvery year the company has filed comes with Alpha Plus.
0.74×0.75×0.74×0.73×
1.38×1.05×0.98×1.06×
25.7%25.1%24.2%24.1%
——1.21×1.23×
——1.48×1.47×
——31.2%33.7%
——31.2%33.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,513.50

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,152 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
30/06/2023
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.730.740.750.74
Interest Burden (Pretax/EBIT) ×1.060.981.051.38
EBIT Margin %24.1224.2025.0625.73
Asset Turnover ×1.231.21——
Financial Leverage (Assets/Equity) ×1.471.48——
ROE (5-step product, year-end total equity) %33.6631.17——
ROE (owners' profit / average owners' equity) %33.5631.18——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.